

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

February, 24 2012  
Commission File Number 001-35203

---

**THERATECHNOLOGIES INC.**

(Translation of registrant's name into English)

---

2310 Alfred-Nobel Boulevard  
Montréal, Québec, Canada  
H4S 2B4  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes       No

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes       No

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_.

---

---

**THERATECHNOLOGIES INC.**

<u>Exhibit</u>	<u>Description</u>
99.1.	Press release dated February 24, 2012.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THERATECHNOLOGIES INC.

By: /s/ Jocelyn Lafond

Name: Jocelyn Lafond  
Title: Vice President, Legal Affairs,  
and Corporate Secretary

Date: February 24, 2012



# News Release

## **Theratechnologies: update on motion for authorization to institute class action against the Company**

**Montreal, Canada – February 24, 2011** – Theratechnologies Inc. (TSX: TH) (NASDAQ: THER) announced today that the Superior Court of Quebec has authorized the institution of a class action and an action based on the secondary market liability provisions of the Quebec Securities Act against Theratechnologies (the “Company”), its current Chairman of the Board of Directors and its former president and chief executive officer on behalf of persons who were shareholders at May 21, 2010 and who sold their common shares of the Company on May 25 or 26, 2010.

The representative of this class of persons is 121851 Canada Inc., a former shareholder of the Company. This person alleges that Theratechnologies did not comply with its continuous disclosure obligations as a reporting issuer by failing to disclose a material change and will have to prove these allegations on the merits.

Despite the granting of such a motion, Theratechnologies is of the view that the allegations against it are entirely without merit and will take all appropriate actions to vigorously defend its position.

### **About Theratechnologies**

Theratechnologies (TSX: TH) (NASDAQ: THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Further information about Theratechnologies is available on the Company’s website at [www.theratech.com](http://www.theratech.com), on SEDAR at [www.sedar.com](http://www.sedar.com) and on the Securities and Exchange Commission’s website at [www.sec.gov](http://www.sec.gov).

-30-

### **Contact:**

Roch Landriault  
NATIONAL Public Relations  
Phone: 514-843-2345

### **Theratechnologies Inc.**

2310 Alfred-Nobel Blvd., Montréal, Québec, Canada H4S 2B4  
Phone: 514 336-7800 • Fax: 514 336-7242 • [www.theratech.com](http://www.theratech.com)